Mounjaro vs Ozempic 2026: Which T2D GLP-1 Wins for Weight Loss, A1C, and Cost? (Head-to-Head Comparison)

Mounjaro (tirzepatide) and Ozempic (semaglutide) are the two most-prescribed GLP-1s in 2026 — both FDA-approved only for Type 2 diabetes, both routinely used off-label for weight loss. In SURMOUNT-5, the only head-to-head trial at FDA-max doses, tirzepatide produced 20.2% body weight loss vs 13.7% for semaglutide at 72 weeks. Mounjaro wins on raw weight loss and A1C reduction; Ozempic wins on long-term safety data (8+ years of cardiovascular and kidney outcome trials in 100,000+ patients). With commercial insurance, both savings cards drop your monthly cost to $25. Off-label cash retail runs $1,069/mo (Mounjaro) vs $998/mo (Ozempic). The cheapest legitimate path for cash-pay patients in June 2026 is compounded — $99/mo for either molecule via Embody, $146/mo via Yucca Health, or $199/mo via TrimRx (Editor's Choice, US-licensed prescribers). Here's the brand-vs-brand head-to-head: how they differ in mechanism, the trial data side-by-side, A1C and weight loss performance, side effects, cost paths, and the cheapest legitimate option for each by your situation.

Quick answer: which should you pick?

What Mounjaro and Ozempic actually are

Both are FDA-approved only for Type 2 diabetes — not for weight loss. Both are prescribed off-label for obesity, and both have on-label sister brands specifically for weight loss:

Practical consequence: if you have T2D, both Mounjaro and Ozempic are appropriate. If you don't have T2D and you want a weight-loss prescription, your prescriber should write Zepbound (tirzepatide for obesity) or Wegovy (semaglutide for obesity) — those are the on-label versions and have dramatically better insurance coverage for non-diabetic patients. For deeper detail see our Zepbound = Mounjaro identity explainer and our Mounjaro off-label weight loss guide.

How they actually work: the GLP-1 vs GLP-1+GIP difference

Ozempic (semaglutide) is a single-receptor agonist. It binds the GLP-1 receptor only, mimicking glucagon-like peptide-1 — a gut hormone released after eating that slows stomach emptying, signals fullness to the brain, and triggers insulin release. Half-life ~1 week (weekly injection).

Mounjaro (tirzepatide) is a dual-receptor agonist. It binds both the GLP-1 receptor AND the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second incretin hormone with effects on insulin secretion, fat metabolism, and (debated) appetite. The dual mechanism explains why tirzepatide produces meaningfully more weight loss and stronger A1C reduction at top doses.

Why this matters clinically: if Ozempic didn't work for you, Mounjaro may — it recruits a separate pathway. If Ozempic worked but you plateaued, escalating to Mounjaro is a defensible next step. The reverse is rarer (Mounjaro tends to outperform on most endpoints), but some patients tolerate semaglutide better than tirzepatide.

Weight loss head-to-head

The SURMOUNT-5 head-to-head (published 2025) is the cleanest comparison: same population, same trial design, both drugs at their FDA-approved max doses for obesity (note: these are Zepbound/Wegovy doses — not Mounjaro/Ozempic T2D max doses, which top out lower). Tirzepatide produced about 47% more weight loss in absolute terms.

For T2D patients specifically: SURMOUNT-2 (tirzepatide in T2D) shows ~14% body weight loss, while STEP-2 (semaglutide in T2D) shows ~9.6%. Tirzepatide wins on weight loss in diabetic patients too, but by a narrower margin than in non-diabetics — likely because T2D physiology partially blunts both drugs' weight effects.

Type 2 diabetes A1C performance

Both drugs are FDA-approved for T2D — this is where their primary trial data lives. The head-to-head:

SURPASS-2 is the key head-to-head: Mounjaro 15mg dropped A1C by 2.30 percentage points vs 1.86 for Ozempic 1mg. The advantage held across all three Mounjaro doses tested. Real-world data confirms: patients with stubbornly elevated A1C on max Ozempic often see further drops when switched to Mounjaro.

Cardiovascular outcomes: here Ozempic has the data edge. SUSTAIN-6 (2016) was the original CV outcome trial for semaglutide; the SELECT trial (2023) extended this with 17,604 patients showing 20% CV event reduction in non-diabetic obese patients. Mounjaro's CV outcome trial (SURPASS-CVOT) is still ongoing — results expected late 2026.

Side effects head-to-head

Both molecules share the same GI-dominant side effect profile because they share the GLP-1 mechanism: nausea, diarrhea, constipation, vomiting, decreased appetite. Most are dose-dependent and resolve as you titrate up slowly.

Where they differ:

• Constipation: somewhat more common on Mounjaro (the GIP receptor effects on gut motility appear additive).
• Severe nausea requiring discontinuation: roughly comparable across trials (4-7% on both at top dose).
• Injection site reactions: equivalent.
• Hypoglycemia (with insulin or sulfonylurea): slightly more common on Mounjaro because the A1C drop is larger; dose-adjust background T2D meds when starting either drug.
• Rare but serious: both carry boxed warnings for thyroid C-cell tumors (rodent data; human risk unestablished). Both should be avoided with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome.

For a deeper safety read see our Ozempic long-term safety analysis — the 90,000-patient cardiovascular and kidney protection data applies to Ozempic specifically and is the strongest long-term safety signal in the class.

Cost paths in June 2026

Mounjaro paths

Ozempic paths

For the full Ozempic alternative breakdown see our Cheapest Compounded Semaglutide guide and How to Get Wegovy Cheaper. For Mounjaro alternatives see our Mounjaro off-label weight loss guide and Cheapest Compounded Tirzepatide ranking.

Key observation: at the compounded floor, both molecules are priced identically. Cost is no longer a tiebreaker between sema and tirz for cash-pay patients in June 2026. The real decision is which molecule clinically fits, which provider you trust, and whether your insurance unlocks a brand savings card path.

Off-label weight loss: the cost reality

If you don't have Type 2 diabetes but your prescriber put you on Mounjaro or Ozempic specifically for weight loss, here's the unsubtle truth: you don't qualify for either savings card. That leaves you paying $1,069/mo (Mounjaro) or $998/mo (Ozempic) cash retail — the most expensive legitimate path to GLP-1 weight loss in the US.

Three workarounds:

1. Get an A1C drawn. Prediabetes (A1C 5.7-6.4) is documented in roughly 1 in 3 American adults. If you have it, the prediabetes diagnosis unlocks T2D-adjacent coding that many plans accept for Mounjaro/Ozempic savings cards. See our Mounjaro $25 path guide. 2. Switch to the on-label sister brand. Brand Zepbound (tirzepatide for obesity) or brand Wegovy (semaglutide for obesity) carry their own savings cards at $25/mo for commercially insured patients with BMI ≥30 or BMI ≥27 + comorbidity. Same molecule, different label, dramatically better coverage. See How to Get Wegovy Cheaper and How to Get Zepbound Cheaper. 3. Move to compounded. Same active molecule, US 503A licensed pharmacy, no T2D code required. $99-$349/mo depending on provider and titration phase.

Compounded provider list (commission-first)

All six tracked telehealth programs offer both semaglutide and tirzepatide. Ranked by what we'd actually recommend:

• TrimRx — Editor's Choice. Semaglutide $199/mo, tirzepatide $299/mo. Flat all-inclusive pricing at any dose. US-licensed prescribers, monthly check-ins. Best for switchers and patients who want clinical supervision.
• Yucca Health. Semaglutide $146/mo on 6-month plan, tirzepatide $258/mo on 6-month plan. Best price-to-credentialing balance.
• MyStart Health. Semaglutide $224/mo with code SELFLOVE25. Brand pathway built-in if you ever transition back to brand Mounjaro/Ozempic/Wegovy/Zepbound.
• MEDVi. Semaglutide $179 first month, $299 refills. Lowest entry point.
• Embody. Semaglutide $99/mo (injection), tirzepatide $149/mo. Cheapest floor; oral GLP-1 gum option for needle-averse patients.
• SkinnyRx. Semaglutide $199/mo, tirzepatide $349/mo. Multi-format delivery (injection, drops, lozenges, tablets).

For the full compounded grid see our cheapest compounded semaglutide ranking and cheapest compounded tirzepatide ranking.

Regulatory caveat: FDA 503B comment period closes June 29, 2026

If you're choosing compounded right now, you should know: the FDA proposed on May 1, 2026 to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The comment period closes June 29, 2026 (6 days from today). If finalized, 503B large-batch compounding ends — 503A patient-specific compounding (which is what the providers above use) continues under separate rules.

Practical implication for the Mounjaro-vs-Ozempic decision: the regulatory risk is identical for both molecules — the proposed rule covers them equally. Don't pick semaglutide hoping it'll dodge enforcement; the FDA is treating them as a class. Full analysis: FDA 503B Compounded Ban Explainer.

Switching from one to the other

If you've been on Ozempic and want to try Mounjaro (or vice versa), the molecules are not interchangeable mg-for-mg. Standard transition protocol:

Ozempic → Mounjaro. Start at Mounjaro 2.5 mg/week (the standard starter dose) even if you were at Ozempic max (2.0 mg). Mounjaro's titration is faster (every 4 weeks) but each step is a meaningful jump. Most T2D patients reach 7.5-10 mg before deciding whether to escalate further.

Mounjaro → Ozempic. Same logic in reverse. Start Ozempic at 0.25 mg/week regardless of your prior Mounjaro dose. The receptors and tolerability profile reset.

Same-molecule continuation (e.g., brand Ozempic to compounded semaglutide): 1:1 mg conversion, no titration restart. See our switching guide for the full Ozempic-to-compounded protocol — the same logic applies to Mounjaro-to-compounded-tirzepatide.

Decision matrix by situation

You have Type 2 diabetes and commercial insurance, A1C uncontrolled on metformin: Mounjaro via Mounjaro Savings Card — strongest A1C drop in head-to-head SURPASS-2 trial. $25/mo.

You have Type 2 diabetes and a history of cardiovascular disease (prior MI, stroke, PAD, heart failure): Ozempic via Ozempic Savings Card — SELECT trial CV outcome data is the strongest in the class. $25/mo.

You have obesity (no T2D), commercially insured, and BMI ≥30: Skip both Mounjaro and Ozempic — they don't qualify under your obesity diagnosis. Ask for Wegovy or Zepbound instead, which carry the same molecules at $25/mo via their respective Savings Cards.

You're cash-pay and want maximum weight loss: Compounded tirzepatide via Embody $149/mo, Yucca $258/mo on 6-month, or TrimRx $299/mo flat.

You're cash-pay and want the lowest monthly cost: Either molecule via Embody at $99/mo for semaglutide or $149/mo for tirzepatide.

You're cash-pay and need an oral option: Semaglutide via Rybelsus ($998 cash, $25 with insurance T2D) or compounded oral routes via Embody or SkinnyRx. No oral tirzepatide on the market (Lilly's orforglipron is a separate molecule — see our Foundayo launch post).

You're on Medicare Part D and qualify for the Bridge Program: Neither — the Medicare Bridge program (launches July 1, 2026) covers Wegovy and Zepbound at $50/mo, not Mounjaro or Ozempic. Talk to your prescriber about switching to the on-label sister brand.

You're a PCOS patient using GLP-1 off-label for insulin resistance: Neither Mounjaro nor Ozempic will be covered by commercial insurance without a separate T2D or obesity ICD-10 code. Compounded is the cleanest path — see our Ozempic for PCOS guide.

FAQ

Is Mounjaro better than Ozempic? For weight loss and A1C reduction, Mounjaro outperforms Ozempic at FDA-max doses in head-to-head trials (SURPASS-2 for A1C, SURMOUNT-5 for weight). For cardiovascular outcome data and long-term safety, Ozempic has the deeper evidence base. "Better" depends on which endpoint matters most for you.

Can I take Ozempic if I don't have diabetes? Yes, but it's off-label. Your prescriber can legally write it, but commercial insurance won't cover it without a T2D code. Cash retail is ~$998/mo. The on-label option for non-diabetic weight loss is Wegovy (same molecule). See How to Get Wegovy Cheaper.

What's the difference between Mounjaro and Zepbound? Same molecule (tirzepatide), same manufacturer (Eli Lilly), same doses. Mounjaro is FDA-approved for T2D; Zepbound is FDA-approved for obesity. Insurance treats them differently — if you have obesity (no T2D), ask for Zepbound. See our Zepbound = Mounjaro explainer.

What's the difference between Ozempic and Wegovy? Same molecule (semaglutide), same manufacturer (Novo Nordisk), different doses. Ozempic tops out at 2.0 mg/week (FDA-approved for T2D); Wegovy goes to 2.4 mg/week (FDA-approved for obesity). For deeper detail see our Ozempic vs Wegovy comparison.

Can I switch from Ozempic to Mounjaro? Yes. Start at Mounjaro 2.5 mg/week regardless of your prior Ozempic dose. Most prescribers titrate every 4 weeks based on tolerance and weight response. Talk to your prescriber about insurance reauth — many plans require a separate PA for tirzepatide.

Is compounded tirzepatide as effective as Mounjaro? The active molecule is the same. Clinical effect depends on dose, adherence, and titration — not on whether the pharmacy is Eli Lilly or a US 503A compounder. Real-world adherence is often higher on compounded programs because the cost barrier is lower.

Which has worse side effects? Very similar profiles (both GLP-1-driven). Mounjaro has slightly higher rates of constipation; Ozempic and Mounjaro are roughly equivalent on nausea, diarrhea, vomiting, and injection site reactions. Real-world tolerability varies more by individual than by drug.

Will FDA pull compounded tirzepatide or semaglutide first? The FDA's May 2026 proposal treats both molecules identically — comment period closes June 29, 2026, with a final rule expected late 2026 at the earliest. Neither molecule has a regulatory edge over the other for compounded patients. See our FDA 503B explainer.

For our full provider grid see the cheapest GLP-1 programs page. For the deeper molecule-level comparison covering all 5 brand names see our tirzepatide vs semaglutide guide. For switching from brand to compounded, see our step-by-step switching guide. For Medicare coverage starting July 1, see our Medicare Bridge enrollment guide.